Molecular data
| Molecular formula | C187H291N45O59 |
|---|---|
| Molecular weight | 4113.58 Da |
| Sequence | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-gGlu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Sequence length | 31 residues |
| CAS / identifier | 910463-68-2 |
| Physical form | Lyophilized powder |
| Available sizes | 20mg |
How it works
GLP-1 Receptor Agonism
Selectively activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. Insulin response scales with glucose, limiting hypoglycemia risk relative to non-incretin secretagogues.
- Glucose-dependent insulin secretion
- Glucagon suppression
- Delayed gastric emptying
Central Appetite Regulation
Engages GLP-1 receptors in the hypothalamus and hindbrain to reduce hunger, increase satiety, and lower overall energy intake — the primary driver of the weight reduction observed in the STEP trial program.
- Reduced appetite
- Increased satiety
- Lower caloric intake
Extended Half-Life Design
A C18 fatty-diacid chain promotes reversible albumin binding and resistance to DPP-4 degradation, extending the plasma half-life to roughly 7 days and enabling a once-weekly dosing profile in research models.
- ~165-hour half-life
- Albumin-binding modification
- DPP-4 resistant
What the research shows
Obesity & Weight Management
In the STEP 1 trial, once-weekly 2.4mg semaglutide produced a mean 14.9% body-weight reduction over 68 weeks — establishing GLP-1 agonism as a leading anti-obesity mechanism.
Wilding et al. 2021
Type 2 Diabetes & Glycemic Control
Semaglutide enhances glucose-dependent insulin secretion and lowers HbA1c, studied extensively across the SUSTAIN clinical program for glycemic management.
Marso et al. 2016
Cardiovascular Outcomes
SUSTAIN-6 reported a reduction in major adverse cardiovascular events among high-risk participants, expanding research interest beyond glucose and weight.
SUSTAIN-6, 2016
Appetite & Reward Circuitry
GLP-1 receptor signaling in the hypothalamus and hindbrain modulates satiety and food-reward pathways, a focus of ongoing neuroscience research.
Davies et al. 2021
Specification
| Compound Class | GLP-1 receptor agonist (incretin mimetic) |
|---|---|
| Research Name | Semaglutide (GLP-1 S) |
| Target | GLP-1 receptor (GLP-1R) |
| Form | Lyophilized powder |
| Molecular Weight | 4,113.58 g/mol |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Half-Life | ~165 hours (~7 days) |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 14 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
Frequently asked questions
What is GLP-1 S?
GLP-1 S is semaglutide, a long-acting and selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central pathways.
How does it differ from tirzepatide and GLP-3 RT?
Semaglutide is a single-receptor (GLP-1) agonist. Tirzepatide is a dual GLP-1/GIP agonist, and GLP-3 RT is a triple GLP-1/GIP/glucagon agonist. The added targets generally correlate with larger weight reductions in trials.
What is the molecular weight and purity?
Semaglutide has a molecular weight of 4,113.58 g/mol. Every vial is supplied at ≥99% purity, verified by HPLC, with a Certificate of Analysis included.
How should it be stored?
Store lyophilized vials at -20°C for long-term stability. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within approximately 14 days.
Is this product for human use?
No. GLP-1 S is sold strictly as a research compound for laboratory and in-vitro use only. It is not intended for human or animal consumption, diagnosis, or treatment.
Literature
- NEJM Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
- NEJM Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6)
- Lancet Semaglutide 2.4mg Once Weekly in Adults with Overweight or Obesity and Type 2 Diabetes (STEP 2)
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.